ES2195573T3 - Preparado farmaceutico solido con estructura multifase para administracion oral de gatifloxacina o sus sales o hidratos farmaceuticamente utilizables y procedimiento para su preparacion. - Google Patents

Preparado farmaceutico solido con estructura multifase para administracion oral de gatifloxacina o sus sales o hidratos farmaceuticamente utilizables y procedimiento para su preparacion.

Info

Publication number
ES2195573T3
ES2195573T3 ES99923491T ES99923491T ES2195573T3 ES 2195573 T3 ES2195573 T3 ES 2195573T3 ES 99923491 T ES99923491 T ES 99923491T ES 99923491 T ES99923491 T ES 99923491T ES 2195573 T3 ES2195573 T3 ES 2195573T3
Authority
ES
Spain
Prior art keywords
salts
preparation
oral administration
solid pharmaceutical
binders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99923491T
Other languages
English (en)
Inventor
Johannes Bartholomaus
Jurgen Betzing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Chemie Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH, Chemie Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2195573T3 publication Critical patent/ES2195573T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Preparado farmacéutico sólido con estructura de varias fases para administración oral, que contiene gatifloxacina o sales o hidratos de ésta farmacéuticamente utilizables y sustancias auxiliares del grupo formado por sustancias de relleno, aglutinantes, lubricantes, aceleradores de desintegración o mezclas de ellos, caracterizado porque la fase interior contiene el principio activo gatifloxacina o sales o hidratos de ésta farmacéuticamente utilizables, junto con sustancias auxiliares del grupo formado por aglutinantes, sustancias de relleno, aglutinantes, aceleradores de desintegración o mezclas de ellos, y como mínimo una fase exterior que consiste en forzosamente como mínimo un acelerador de desintegración y otras sustancias auxiliares del grupo formado por como mínimo un lubricante, en caso dado sustancias de relleno y/o en caso dado aglutinantes.
ES99923491T 1998-05-09 1999-04-29 Preparado farmaceutico solido con estructura multifase para administracion oral de gatifloxacina o sus sales o hidratos farmaceuticamente utilizables y procedimiento para su preparacion. Expired - Lifetime ES2195573T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19820801A DE19820801A1 (de) 1998-05-09 1998-05-09 Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten

Publications (1)

Publication Number Publication Date
ES2195573T3 true ES2195573T3 (es) 2003-12-01

Family

ID=7867223

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99923491T Expired - Lifetime ES2195573T3 (es) 1998-05-09 1999-04-29 Preparado farmaceutico solido con estructura multifase para administracion oral de gatifloxacina o sus sales o hidratos farmaceuticamente utilizables y procedimiento para su preparacion.

Country Status (27)

Country Link
US (1) US6291462B1 (es)
EP (1) EP1077703B1 (es)
JP (1) JP2002514600A (es)
KR (1) KR100587210B1 (es)
CN (1) CN1198615C (es)
AR (1) AR019279A1 (es)
AT (1) ATE235242T1 (es)
AU (1) AU753482B2 (es)
BR (1) BR9910350A (es)
CA (1) CA2325636A1 (es)
CO (1) CO5050341A1 (es)
DE (2) DE19820801A1 (es)
DK (1) DK1077703T3 (es)
ES (1) ES2195573T3 (es)
HU (1) HUP0101597A3 (es)
IL (1) IL139512A0 (es)
MY (1) MY118569A (es)
NO (1) NO20005385L (es)
NZ (1) NZ507968A (es)
PE (1) PE20000480A1 (es)
PL (1) PL343936A1 (es)
PT (1) PT1077703E (es)
RU (1) RU2226394C2 (es)
SK (1) SK16772000A3 (es)
UA (1) UA60364C2 (es)
WO (1) WO1999058129A1 (es)
ZA (1) ZA200006440B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025976A1 (es) 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
US6413969B1 (en) * 2000-09-13 2002-07-02 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US6589955B2 (en) * 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
CA2508792C (en) 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2004082586A2 (en) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
WO2005021000A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Solid oral dosage forms of gatifloxacin
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US20060247255A1 (en) * 2005-05-02 2006-11-02 Patel Satishkumar A Method for preparing a stable gatifloxacin composition
EP1909736B1 (en) * 2005-08-02 2014-11-12 Baxter International Inc. Oxygen indicator for use in medical products and packet containing oxygen indicator
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
CN100415212C (zh) * 2006-07-21 2008-09-03 哈药集团制药总厂 一种含乳酸卡德沙星的口服制剂
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH089597B2 (ja) * 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
FI20021701L (fi) * 1991-01-30 2002-09-24 Wellcome Found Veteen dispergoituvia tabletteja
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JP2647338B2 (ja) * 1993-02-10 1997-08-27 武田薬品工業株式会社 素錠およびその製造方法
US5436253A (en) * 1993-09-08 1995-07-25 Daiichi Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives and mycotic infections
JP3893439B2 (ja) * 1994-12-19 2007-03-14 第一製薬株式会社 徐放性粒状製剤およびその製造方法
JP3449658B2 (ja) * 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation

Also Published As

Publication number Publication date
CO5050341A1 (es) 2001-06-27
IL139512A0 (en) 2001-11-25
SK16772000A3 (sk) 2001-05-10
US6291462B1 (en) 2001-09-18
UA60364C2 (uk) 2003-10-15
EP1077703A1 (de) 2001-02-28
DK1077703T3 (da) 2003-06-23
MY118569A (en) 2004-12-31
HK1033281A1 (en) 2001-08-24
PT1077703E (pt) 2003-08-29
EP1077703B1 (de) 2003-03-26
NZ507968A (en) 2002-12-20
NO20005385D0 (no) 2000-10-26
AU4035299A (en) 1999-11-29
CA2325636A1 (en) 1999-11-18
CN1198615C (zh) 2005-04-27
BR9910350A (pt) 2001-09-25
WO1999058129A1 (de) 1999-11-18
DE19820801A1 (de) 1999-11-25
ATE235242T1 (de) 2003-04-15
JP2002514600A (ja) 2002-05-21
PE20000480A1 (es) 2000-05-20
ZA200006440B (en) 2002-02-08
AU753482B2 (en) 2002-10-17
KR100587210B1 (ko) 2006-06-08
CN1300216A (zh) 2001-06-20
AR019279A1 (es) 2002-02-13
NO20005385L (no) 2000-10-26
HUP0101597A3 (en) 2003-01-28
DE59904737D1 (de) 2003-04-30
RU2226394C2 (ru) 2004-04-10
HUP0101597A2 (hu) 2001-11-28
PL343936A1 (en) 2001-09-10
KR20010043408A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
SV2002000248A (es) Composicion farmaceutica suministrando concentracion aumentada de la droga ref. pc10755ajtj/bb
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
ES2126536B1 (es) "preparado farmaceutico para administracion intranasal y procedimientopara su produccion".
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
IL138767A0 (en) Anticancer compositions
BRPI0709847B8 (pt) composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
BR0016496A (pt) Sistema de armazenamento para medicamentos em forma de pó e inalador equipado para isso
CO5050341A1 (es) Forma medicamentosa solida de estructura polifasica para aplicacion oral que contiene gatifloxacina o sus sales o hidratos farmaceuticamente aplicables, y procedimiento para su preparacion
CY1111153T1 (el) Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης
AR034346A1 (es) Capsulas para inhalacion
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
CO5011053A1 (es) Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
BRPI0508125A (pt) formulação de alcalóide, método para melhorar a eficácia de um alcalóide, uso do produto da reação de um ou mais alcalóides com um mais derivados de fosfato de um ou mais agentes de transferência de elétrons, junto com excipientes e composição farmacêutica
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
PA8548301A1 (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos